CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Takeda Pharmaceuticals USA Inc. v. Watson Laboratories Inc.

1:14-cv-00268

Overview

Case Number 1:14-cv-00268
Filing Date 2014-02-27
Status Terminated
Termination Date 2016-02-29
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Watson Laboratories Inc. Operating Company

Represented By

6 Attorneys Listed

Russell J. Rigby

UNDELIVERABLE EMAIL 12/1/2017

Matthew J. Goggin

Email: mgoggin@carlsoncaspers.com

Mark D. Schuman

UNDELIVERABLE EMAIL 8/30/2019

Alexandra J. Olson

Email: aolson@carlsoncaspers.com

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Melanie K. Sharp

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6681
Fax: +1 (302) 571-1253

Rodney Square, 1000 North King Street

Actavis Inc. Operating Company

Represented By

2 Attorneys Listed

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Melanie K. Sharp

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6681
Fax: +1 (302) 571-1253

Rodney Square, 1000 North King Street

Counter Defendant

Takeda Pharmaceuticals USA Inc. Operating Company

Represented By

8 Attorneys Listed

Heather E. Takahashi

Email: heather.takahashi@mto.com

Hannah Dubina

Email: hannah.dubina@mto.com

Elizabeth A. Laughton

Email: elizabeth.laughton@mto.com

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Eric K. Chiu

Email: eric.chiu@mto.com

Tryn T. Stimart

Email: tstimart@gibbonslaw.com

Amy L. Greywitt

Email: amy.greywitt@mto.com

Daniel Marcus Attaway

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4365

1313 North Market Street, Suite 1200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

17 Patents

There are 17 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7619004
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2008-12-03
Issued: 2009-11-17
Active (2.0 yrs remaining)
Expires: 2028-12-03
US7601758
Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Filed: 2009-02-10
Issued: 2009-10-13
Active (2.2 yrs remaining)
Expires: 2029-02-10
US7820681
Methods for concomitant administration of colchicine and a second active agent
Filed: 2009-02-17
Issued: 2010-10-26
Active (2.2 yrs remaining)
Expires: 2029-02-17
US7915269
Methods for concomitant administration of colchicine and a second active agent
Filed: 2010-08-18
Issued: 2011-03-29
Active (3.7 yrs remaining)
Expires: 2030-08-18
US8093297
Methods for concomitant administration of colchicine and a second active agent
Filed: 2011-04-22
Issued: 2012-01-10
Active (4.4 yrs remaining)
Expires: 2031-04-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

28

Dispositive

1

Granted

2

Denied

0

Pending / Review

24

Motions by Category

Procedural / Extension Motion 13 Claim Construction / Markman Filing 14 Motion for Summary Judgment (Infringement) 1

Key Dispositive Motions & Rulings

Motion for Summary Judgment (Infringement) Pending / Under Review
Letter to The Honorable Sue L. Robinson from Katherine C. Lester regarding Par and Watson's request to submit a Motion for Partial Summary Judgment of Non Infri...
Entry #112 • 2015-02-19 Document →
Claim Construction / Markman Filing Pending / Under Review
MEMORANDUM ORDER re: claim construction. Signed by Judge Sue L. Robinson on 6/1/2015. Associated Cases: 1:13-cv-01524-SLR, 1:13-cv-01729-SLR, 1:14-cv-00268-SLR(...
Entry #147 • 2015-06-01 Document →
Claim Construction / Markman Filing Pending / Under Review
REDACTED VERSION of 140 Claim Construction Surreply Brief [Defendants' Surreply Brief on Claim Construction] by Watson Laboratories Inc.. (Vrana, Robert) (Enter...
Entry #143 • 2015-05-01 Document →
Claim Construction / Markman Filing Pending / Under Review
REDACTED VERSION of 141 Appendix [Defendants' Surreply Claim Construction Appendix] by Watson Laboratories Inc.. (Vrana, Robert) (Entered: 05/01/2015)
Entry #144 • 2015-05-01 Document →
Claim Construction / Markman Filing Pending / Under Review
[SEALED] CLAIM CONSTRUCTION SURREPLY BRIEF re 121 Claim Construction Opening Brief filed by Watson Laboratories Inc.. (Vrana, Robert) (Entered: 04/24/2015)
Entry #140 • 2015-04-24 Document →
Claim Construction / Markman Filing Pending / Under Review
[SEALED] APPENDIX re 140 Claim Construction Surreply Brief by Watson Laboratories Inc.. (Attachments: # 1 Exhibits S-V)(Vrana, Robert) (Entered: 04/24/2015)
Entry #141 • 2015-04-24 Document →

Docket Entries

(187 total)
Pleading / Complaint

COMPLAINT filed against Actavis Inc., Watson Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1470293.) - filed by Takeda Pharmaceuticals USA Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Civil Cover Sheet)(cla, ) (Attachment 6 replaced on 3/4/2014) (rwc). (Entered: 02/27/2014)

Entry #1 • 2014-02-27
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cla, ) (Entered: 02/27/2014)

Entry #2 • 2014-02-27
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/31/14. Date of Expiration of Patent: SEE FORM.Thirty Month Stay Deadline: 7/31/2016. (cla, ) (Entered: 02/27/2014)

Entry #3 • 2014-02-27
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,619,004; US 7,601,758; US 7,820,681; US 7,915,269; US 7.964.647; US 8,093,297; US 7,981,938; US 8,093,296; US 8,093,297; US 8,097,655; US 8,415,395; US 8,415,396; US 8,440,721; US 8,440,722. (cla, ) (Entered: 02/27/2014)

Entry #4 • 2014-02-27
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited, Corporate Parent Takeda American Holdings Inc. for Takeda Pharmaceuticals USA Inc. filed by Takeda Pharmaceuticals USA Inc.. (cla, ) (Entered: 02/27/2014)

Entry #5 • 2014-02-27
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc